I won't put you on blast but I heartily disagree with you.
The Mida Multi Tool is pretty much the exact same gun it was in Year 1 but it didn't get near as much use.
Why?
First, the Vex Mythoclast and Suros Regime reigned supreme. They actually were overpowered at first. Then came Thorn and The Last Word. They also were overpowered.
Mida isn't OP because none of Midas perks are all that great to begin with. It's base stats are average at best. Third Eye can be found on any number of Legendaries, its middle perks aren't anything to brag about, and its signature perk boosts speed and trigger pull.
It doesn't have poison, life gain, or a way to boost damage.
It's just popular. It's always been GOOD but always was kept down by Thorn and the others.
This meta is arguably the most balanced it's ever been. That may not be saying much but it's improvement.
When Trials first came out, Thorn dominated. Like to 80% of the meta. TLW was second in terms of usage with Red Death rounding out the Top 3. If you wanted to have a legit chance in PvP, you'd start with Thorn simply because it gave you the best chance to win.
Last night in Trials, my first Trials in Y2, I was killed by Mida, Doctrine, Red Death, Hung Jury, The Last Word and I'm sure there were others that I cant remember.
Unlike Y1 Trials, however, I wasn't consistently killed by a green poison on my screen.
Your role as a moderator enables you immediately ban this user from messaging (bypassing the report queue) if you select a punishment.
7 Day Ban
7 Day Ban
30 Day Ban
Permanent Ban
This site uses cookies to provide you with the best possible user experience. By clicking 'Accept', you agree to the policies documented at Cookie Policy and Privacy Policy.
Accept
This site uses cookies to provide you with the best possible user experience. By continuing to use this site, you agree to the policies documented at Cookie Policy and Privacy Policy.
close
Our policies have recently changed. By clicking 'Accept', you agree to the updated policies documented at Cookie Policy and Privacy Policy.
Accept
Our policies have recently changed. By continuing to use this site, you agree to the updated policies documented at Cookie Policy and Privacy Policy.